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BACKGROUND: Many opioid-dependent patients do
not receive care for addiction issues when hospitalized
for other medical problems. Based on 3 years of clinical
practice, we report the Transitional Opioid Program
(TOP) experience using hospitalization as a “reachable
moment” to identify and link opioid-dependent persons
to addiction treatment from medical care.
METHODS: A program nurse identified, assessed, and
enrolled hospitalized, out-of-treatment opioid-depen-
dent drug users based on their receipt of methadone
during hospitalization. At discharge, patients transi-
tioned to an outpatient interim opioid agonist program
providing 30-day stabilization followed by 60-day taper.
The nurse provided case management emphasizing HIV
risk reduction, health education, counseling, and med-
ical follow-up. Treatment outcomes included opioid
agonist stabilization then taper or transfer to long-term
opioid agonist treatment.
RESULTS: From January 2002 to January 2005, 362
unique hospitalized, opioid-dependent drug users were
screened; 56% (n = 203)met eligibility criteria and enrolled
into the program. Subsequently, 82% (167/203) pre-
sented to the program clinic post-hospital discharge; for
59% (119/203) treatment was provided, for 26% (52/203)
treatment was not provided, and for 16% (32/203)
treatment was not possible (pursuit of TOP objectives
precluded by medical problems, psychiatric issues, or
incarceration). Program patients adhered to a spectrum of
medical recommendations (e.g., obtaining prescription
medications, medical follow-up).
CONCLUSIONS: The Transitional Opioid Program (TOP)
identified at-risk hospitalized, out-of-treatment opioid-
dependent drug users and, by offering a range of
treatment intensity options, engaged a majority into
addiction treatment. Hospitalization can be a “reach-
able moment” to engage and link drug users into
addiction treatment.
KEY WORDS: harm reduction; opioid dependence; methadone;
addiction treatment.
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INTRODUCTION
Opioid-dependent individuals are frequent users of hospital
services for acute medical conditions.1–3 When hospitalized, they
are often not engaged in addiction treatment.4 They avoid
hospitalization for fear of withdrawal,5 and if hospitalized,
resumedruguse at discharge.6However, hospitalizationprovides
an opportunity to improve and coordinate addiction treatment. A
hospital-based program could identify opioid-dependent
patients, engage them in addiction treatment, and mitigate
high-risk behaviors. Hospitalization is a “reachable moment”—
to engage out-of-treatment individuals whose acute illness may
render them willing to consider addiction treatment.7,8
Methadone is recommended for acute withdrawal in opioid-
dependent patients to reduce early hospital departures and
facilitate acute treatment.4,9,10 However, brief methadone expo-
sure does not improve low abstinence rates (e.g., 80% of opioid-
dependant individuals relapsewithin 1 year of detoxification).11,12
Moreover, opioid agonists administered during hospitalization do
not result in adequate ongoing abstinence after discharge.8
Research programs targeting hospitalized opioid-dependent
patients have combined engagement with intensive, structured
substance use treatment.13–15 However, patients ambivalent
about formal addiction treatment may be disinclined to enroll
or remain in these types of programs. We created a clinical
model to improve comprehensive health and lifestyle outcomes
(e.g., linkage and adherence to treatment, reduction in un-
healthy substance use behaviors) and promote low-threshold
access that might engage reluctant patients. In 2001, the
Transitional Opioid Program (TOP) was created for out-of-
treatment, opioid-dependent patients hospitalized in an urban
teaching hospital in coordination with but independent of an
affiliated Opioid Treatment Program (OTP). TOP had three
aims: (1) improve access to opioid addiction treatment; (2)
provide risk reduction strategies to prevent HIV, hepatitis, and
sexually transmitted diseases; (3) increase hospital discharge
plan adherence. TOP identified hospitalized out-of-treatment,
opioid-dependent patients and linked them to outpatient,
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interim opioid agonist addiction treatment, medical care, risk-
reduction services, and individualized case management.
Components of this clinical program and the initial 3-year
experience are described.
METHODS
The program model was based on a conceptual framework that
included the following important components: (1) interim
opioid replacement therapy; (2) individualized case manage-
ment; (3) group public health education; (4) principles of
motivational interviewing and harm reduction.
Interim Opioid Agonist Treatment
Opioid agonists facilitated patient engagement in the program
by mitigating withdrawal, craving, and illicit drug procure-
ment. The program worked to reduce risk of harm from
injection drug use and permit participants to reflect on their
circumstances, consider behavior change, and formulate
goals.
Individualized Case Management
Individualized case management marshaled resources for
vulnerable participants temporarily stabilized on opioid-agonist
therapy. After hospitalization, patients face additional barriers to
recovery (e.g., lack of long-term treatment availability, lack of
insurance, homelessness). Case management provided a safe
environment for both formal and informal addiction counseling.
Unstructured interactions provided opportunities to address
ambivalence to counseling.
Group Health Education
Group health education was an essential program component
as patients face many risk-laden decisions.16,17 Drug users
transmit information via “word-of-mouth” and may use knowl-
edge gained through health education to reduce risky beha-
viors.18 Group education maximized staff efficiency and
reinforced therapeutic messages.
Principles of Motivational Interviewing and Harm
Reduction
The program used principles recommended by the Institute of
Medicine including engaging patients in all states of readiness
to change, setting intermediate goals, working collaboratively
with patients towards them, and responding to individual
needs.19 This approach was used to educate participants
about prevention of sexually transmitted infections, increase
linkage to mental health and primary medical care, and
enhance adherence to medical treatment. Intermediate behav-
ioral goals and harm reduction methods were employed to
enhance readiness to change and decrease medical complica-
tions.20,21
The program nurse made frequent “check-in” visits during
the hospitalization because experience suggested that repeat-
ed low-pressure engagement combined with motivational
interviewing methods increased enrollment and enhanced
outcomes for ambivalent participants. Incremental progress
by achieving intermediate outcomes was considered produc-
tive and consistent with the transtheoretical model of behavior
change.22 Any reduction of harmful behaviors or increased
involvement in treatment or assistance services was positively
emphasized.23
Transitional Opioid Program Phases
Phase 1. Inpatient—Identification, Screening, Assessment,
and Enrollment. Phase 1 (during hospitalization) included
identification, screening, comprehensive medical and psychosocial
assessment, social service evaluation, daily visitation, substance
abuse treatment education, and methadone induction and
stabilization. The program nurse employed clinical judgment
while determining program eligibility in interested individuals.
Phases 2. Outpatient Days 1 Through 30—Stabilization
and Maintenance. Phase 2 (at the OTP during days 1 to 30
after hospital discharge) included methadone dose reassessment
and titration, individualized case management, and
comprehensive care planning. The program nurse transferred
medication and medical information (last methadone dose,
admission documentation, laboratory results, PPD status, and
urine toxicology) to the OTP. Patients received daily observed
methadone at the OTP up to a maximum daily dose (80 mg) to
relieve withdrawal symptoms and opioid craving. The dose of
80 mg was the highest dose from which a 60-day detoxification
was estimated to be tolerable. The first day of outpatient
methadone administration, the program nurse oriented patients
to the OTP and daily administration staff.
Participation in case management, education emphasizing
risk reduction, health education, and formal addiction
counseling was encouraged but not required. Supervised urine
drug testing and medical follow-up were recommended. The
program nurse monitored patients, offered support and infor-
mal treatment counseling, made referrals, and managed
psycho-social crises. A physician met participants the first
week at the OTP. The program nurse facilitated weekly public-
health oriented educational group discussions at the OTP
addressing common challenges (e.g., relapse prevention).
Participants also met the program nurse weekly for individual
15-min “check-in” sessions. Methadone was administered
within 15 min of the group session to encourage attendance.
OTP nurses monitored participants daily during methadone
administration and were reminded by an electronic alert to
direct participants to keep their weekly “check-in” appoint-
ment with the program nurse.
Phase 3. Outpatient Days 31 Through 90—Taper or Titration
and Transition to Long-Term Addiction Treatment. Phase 3 (days
31-90) included initiation of a 60-day methadone taper or
preparation for transfer to another OTP. The program nurse
provided both scheduled and drop-in counseling sessions
during Phases 2 and 3. As case manager, the program nurse
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supported and guided participants, helping them clarify,
define, and achieve personal treatment goals. Participants set
measurable, achievable goals and identified action steps to
meet them (e.g., decrease methadone dose 5 mg per week, keep
next doctor appointment). The plan was reviewed weekly and
revised based on progress, physical and mental health status,
housing and legal status. The program nurse assisted and
advocated for the participants to ensure that action steps were
met as planned. Participants, in consultation with the program
nurse, decided to taper or transfer to a long-term OTP based
on individual preference, availability of treatment slots,
insurance status, staff recommendations, and employment
and family issues.
Outpatient Objectives During Phase 2 and 3. Phases 2 and 3
addressed educational issues, behaviors, and service
utilization. Examples included discharge medical treatment
adherence (obtaining prescriptions and medical follow-up);
harm reduction (needle sharing avoidance, needle exchange
program enrollment, vein care, overdose prevention); condom
use; HIV counseling and testing; hepatitis C and HIV health
education; and addiction treatment education (acupuncture,
community resources, methadone, relapse prevention,
smoking cessation, recovery tools, and 12-step groups).
Design and Implementation
The Program Nurse. The program nurse consistently engaged
patients from hospital enrollment to program completion.
Daily visits helped patients establish trust and rapport,
address expectations and concerns, and optimize methadone
dosing. The program nurse (DB), available to patients and all
clinical staff by pager, was supervised by the program
physician director (CWS). During Phase 2 and 3, the nurse
reviewed treatment plans, assessed dosing, answered
questions, and provided emotional support for participants at
the OTP. OTP physicians oriented participants to opioid
agonist treatment, performed assessments, and collaborated
with the program nurse on the treatment plan. The program
nurse provided ongoing education to the OTP clinic nursing
staff about the philosophy and policies of the program to
maintain support for TOP as a distinct program with specific
goals within the larger OTP.
To determine program eligibility, hospitalized patients were
screened for receipt of daily low-dose methadone (20–40 mg).
Patients were identified through the inpatient computerized
medication ordering system. The program nurse reviewed
individual medical records and discussed the potential for
enrollment with clinical staff. Eligibility criteria included: (1)
active opioid use and dependence; (2) not currently enrolled in
an opioid treatment program; (3) no chronic use of non-
prescribed benzodiazepines; (4) no current alcohol-depen-
dence; (5) no active psychosis or suicidal/homicidal ideation.
Program participation did not guarantee the opportunity for
long-term OTP enrollment. Methadone dosing in the OTP
program was based on federal regulations authorizing up to
120 days of methadone without concurrent routine drug
testing, counseling or rehabilitation services for individuals
awaiting comprehensive treatment.24
Outcome Definitions. Important medical and psychosocial
patient outcomes were determined after program design and
implementation and were reported for descriptive purposes
only. A comparison group was not available. Outcomes were
defined in terms of whether or not treatment was provided to
participants. All outcomes were classified as “Treatment
Provided” (e.g., enrolled in long-term OTP), “Treatment Not
Provided” (e.g., loss to follow-up), or “Treatment not Possible”
because medical or psychiatric issues took precedence (e.g.,
too medically or mentally ill or incarcerated).
Data Collection. Data from the program case-management
database and the hospital’s information system were extracted
and transferred to a research database. Unique patients from
the program’s first 3 years are reported. The Institutional
Review Board of Boston Medical Center approved this study.
RESULTS
Patient Characteristics
Between January 2002—January 2005, 362 unique patients
were screened from admissions to the medical service of
Boston Medical Center that received methadone for opiate
withdrawal treatment and were neither enrolled in an OTP nor
prescribed methadone for pain control (Fig. 1). Average hospi-
talization was 5.7 days (SD 7.3; range 1-76 days). Average daily
in-patient census (Phase 1) was 2, and average program
census (Phase 1-3) was 17. The average length of participation
N = 74/362 (20%)
N = 36/203 (18%)
N = 85/288 (30%)
Phase 1
Phase 2 & 3
N = 203/288 (70%)
First Visit at Methadone Clinic
N = 167/203 (82%)
N = 288/362 (80%)
N = 362
Figure 1. Screening and enrollment schema of the transitional
opioid program.
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in the entire program (Phases 1-3) was 60 days (SD 38; range,
1-154 days).
Unique Screened Patients
Of the 362 unique screened patients, there were 67%males: 50%
White, 45% African-American, or 5% other; 24% self-reported
Hispanic ethnicity. Mean age was 40 years. Medical conditions
typical for this population were noted.1,2 Housing information
available from a subset of patients assessed in the latter period of
follow-up revealed 60% (69/115) “any homelessness in the
previous 6 months,” 44% (51/115) “currently homeless,” and
65% (75/115) “anticipated homelessness in the next 6 months.”
Of the screened patients, 20% (74/362) were ineligible for the
following reasons: active benzodiazepine abuse 24% (18/74);
alcohol dependence with active alcohol use 24% (18/74); unsta-
ble psychiatric co-morbidity 14% (10/74); opioid use for less than
1 year 12% (9/74); medical illness severity 9% (7/74); non-daily
opioid use 7% (5/74); other reasons 9% (7/74).
Eligible Patients
Of the 362 screened patients, 80% (288) were eligible for
enrollment. However, 30% (85/288) declined program enroll-
ment because they “desire residential treatment” 48% (41/85);
“oppose methadone treatment” 24% (20/85); “have no interest
in treatment at this time” 15% (13/85); “live too far away from
the methadone clinic” 9% (8/85); or “want AA/NA only” 4% (3/
85). Overall, 89% of those eligible (255/288) reported interest
in addiction treatment.
Patients Enrolled in Hospital (Phase 1)
Of the remaining 203 patients that were eligible and accepted
enrollment, 82% (167/203) became participants at theOTP clinic
after hospitalization. Among the 18% (36/203) who “dropped-
out” (failed to transition to the OTP—Phase 2), 44% (16/36) did
not appear for the first dose, 22% (8/36) left the hospital “against
medical advice,” 11% (4/36) became too ill (e.g., transferred to
ICU or long-term nursing facility), 8% (3/36) were discharged to
another facility, and 14% (5/36) dropped out for other reasons.
Overall Outcomes of Participants Enrolled
in Hospital (Phase 1)
Of 203 participants initially enrolled during hospitalization,
treatment was provided to 59% (119/203), treatment was not
provided to 26% (52/203), or treatment was not possible 16%
(32/203).
Short-Term Substance Abuse Treatment Outcomes
of Program Participants (Phase 2 and 3)
Among the 203 enrolled participants who entered Phase 2 and
had treatment provided, 35% (71/203) enrolled in a long-term
OTP, 15% (31/203) completed methadone taper, 4% (9/203)
entered outpatient or residential substance abuse treatment,
and 2% (5/203) entered an inpatient detoxification facility.
Among 52 participants initially enrolled but who were not
provided treatment, 46% (24/52) did not show at the metha-
done clinic or left the hospital against medical advice, and 54%
(28/52) did not show at the OTP clinic for 14 consecutive days
or were discharged for behavioral issues.
Other Short-Term Outcomes
Phase 2 participants (n = 167) attained other outcomes
including: obtained discharge prescriptions, 56% (94/167);
attended primary care appointment, 54% (90/167); attended 2
or more group counseling sessions, 50% (84/167); enrolled in
a needle-exchange program, 17% (28/167); attended a 12-step
program, 16% (27/167); became employed, 16% (27/167).
DISCUSSION
The Transitional Opioid Program identified, recruited, engaged,
and linked hospitalized out-of-treatment opioid-dependent
patients to addiction care using interim opioid agonist treatment,
individualized case management, and both scheduled and drop-
in counseling. Most enrolled participants, 82% (167/203), pre-
sented for treatment at the OTP clinic after hospital discharge
suggesting that an unmet need was addressed. The program
employed minimal enrollment standards that did not require
commitment to long-term OTP.
Other investigators have studied methods to engage opioid-
dependent patients in addiction treatment. A randomized
clinical trial targeting out-of-treatment opioid users identified
and linked 126 selected individuals to methadone mainte-
nance using four strategies: case management, free treatment
voucher, case management plus voucher, or usual care for
6 months. At 3 months, long-term OTP enrollment was “usual
care” (11%), case management alone (47%), treatment voucher
(89%), and both case management and voucher (93%). En-
hanced treatment access using a voucher was twice as effective
as case management alone in linking hospitalized addicts to
drug abuse treatment.25 Vouchers also enhanced 6-month
methadone treatment enrollment rates for patients seeking
addiction treatment.26 Schwartz et al. demonstrated that more
than three-quarters of 319 heroin-dependent adults on an
OTP waitlist randomly assigned to interim methadone
remained engaged and entered a long-term OTP.27,28
TOP differs from previous reports in a few important ways.
Populations identified by ours and other programs were
similar in the range of need and readiness to change; however,
TOP engaged non-treatment seeking, opioid-dependent
patients ambivalent about substance abuse treatment. More-
over, the program approached ambivalence as a dynamic state
and by use of interim opioid agonist therapy provided patients
an opportunity to address indecision about addiction treat-
ment and modify their readiness to change. Other “programs”
described in the literature consisted of clinical trials that
created linked but distinctly separate inpatient and outpatient
services that were designed to test different methods and
settings for engaging patients. These programs had different
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objectives, enforced stricter eligibility requirements, or used
longer duration and standard OTP structure. In contrast to
reports in the literature, our program encouraged but did not
require monthly urine drug testing or formal counseling (i.e.,
no minimum engagement requirements). Similarly, urine
testing, if obtained and positive, did not impact program
participation. Moreover, duration of participation in the pro-
gram was roughly half that of other interim opioid-agonist
therapy programs.7–27 Similar to programs described by Aszalos
and O’Toole, TOP participants were hospitalized; however, our
program employed a single nurse who performed inpatient initial
contact and screening through to final outpatient taper or referral
to maintenance treatment in an OTP.13–15
The program provided the hospital-based clinical team an
option for addressing opioid dependence. The TOPmodel appears
sustainable and replicable using a modest staffing model (one
nurse) and basic coordination within existing treatment services.
The first 3 years of the program were supported by funding from
the Massachusetts Department of Public Health. In year 4, the
Boston Public Health Commission assumed program costs.
Although data to examine health services implications of the
program (e.g., hospital re-admissions) were not available, such
analyses warrant further study.
Limitations
The program was not available for recruitment at all times but
rather only 4 days/week, 8 h/day nor on all services (i.e., only
medical service). The TOP model represents a single health care
system’s experience and awaits replication. Long-term outcomes
of the model could not be determined because subjects did not
receive long-term follow-up. Use of electronic medication reports
was important and enhanced efficiency, but was not essential to
the TOPmodel, and other enrollment screeningmethods could be
devised to facilitate replication. Quantification of the relative
improvement in addiction treatment and other outcomes was
not possible because a comparison group was not available.
However, most participants were not seeking treatment when
hospitalized, and few would have received addiction treatment
had they not been enrolled in the program.
CONCLUSIONS
The Transitional Opioid Program (TOP) program model is
based on collaboration between a traditional acute inpatient
facility and an outpatient addiction treatment program. This
model of a transitional opioid program (TOP) engaged and
linked many opioid-dependent patients to appropriate addic-
tion and medical care by providing interim opioid agonist
treatment while offering a range of treatment intensity options
along with exposure to case management and health educa-
tion focused on personal risks. Given the descriptive nature of
this report, its findings should be considered preliminary and
hypothesis-generating, and further study will be required to
evaluate model efficacy and long-term outcomes.
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